Ottawa, November 14, 2023 – Innovative Medicines Canada (IMC) is pleased to announce that Brigitte Nolet, President and CEO of Roche Canada Pharma, has been selected as Chair of its Board of Directors.
“Brigitte has been a longstanding champion of the life sciences sector and the critical role it plays in driving health innovation to improve patient outcomes,” said David Renwick, Interim President of IMC. “There has never been a more important time to rethink our approach to health care in Canada, and Brigitte’s leadership will be integral as we work alongside governments, health-care stakeholders, and patients to better serve Canadians with timely access to innovative medicines.”
Brigitte, a Welland, Ontario native, has held a number of progressive leadership roles within Roche, locally and globally, since joining the company in 2006. In her various leadership roles, Brigitte has established a global policy function, supported the evolution of Roche’s work with global health institutions like the World Bank and the World Health Organization, represented the company on numerous global and local trade association committees, led Roche’s early participation in the industry’s Noncommunicable Disease (NCD) Access Initiative to bring oncology medicines to low and lower middle-income countries, and supported multiple product launches. In addition to her role as Board Chair, Brigitte is also a board member of BIOTECanada and a member of the partner advisory board for the Healthcare Businesswomen’s Association.
“I am deeply committed to our industry’s vision of enhancing access to life-saving medicines for patients and improving the total health of Canada,” said Brigitte Nolet, President and CEO of Roche Canada Pharma. “I look forward to working hand-in-hand with all our valued partners as the Chair of Innovative Medicines Canada to help bring us closer to a day where Canadian patients have optimal access to the life-changing innovations that we are so privileged to bring.”
Brigitte will serve a two-year term as Board Chair.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 48 companies that invest nearly $1.4 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
For further information: media@imc-mnc.ca
